Eyam Welcomes Wolfgang Koester to Board of DirectorsBy Samad Raza|2024-03-18T21:08:29+00:00March 18th, 2024|
Eyam Announces Artificial Intelligence Research Facility in Partnership with Mitacs Eyam Announces Artificial Intelligence Research Facility in Partnership with MitacsBy Ryan M. Thomas|2023-05-31T18:37:56+00:00May 31st, 2023|
Eyam Announces Partnership with Mitacs to Fund Next Generation COVID-19 Vaccine Technologies Eyam Announces Partnership with Mitacs to Fund Next Generation COVID-19 Vaccine TechnologiesBy Ryan M. Thomas|2022-10-11T16:06:51+00:00October 11th, 2022|
Eyam Acquires Option for Novel Antibody Biologic Therapeutics for the Treatment of Leukemia and Lymphoma Eyam Acquires Option for Novel Antibody Biologic Therapeutics for the Treatment of Leukemia and LymphomaBy Ryan M. Thomas|2022-10-07T16:04:15+00:00September 27th, 2022|
Eyam Vaccines And Immunotherapeutics Embarks On New Licensing Agreement For Creating Innovative Vaccine Technologies Eyam Vaccines And Immunotherapeutics Embarks On New Licensing Agreement For Creating Innovative Vaccine TechnologiesBy Ryan M. Thomas|2022-10-04T16:16:21+00:00August 3rd, 2022|
Eyam’s Chief Scientific Officer, Dr. Wilfred Jefferies, Inducted in the National Academy of Inventors Eyam’s Chief Scientific Officer, Dr. Wilfred Jefferies, Inducted in the National Academy of InventorsBy Ryan M. Thomas|2022-06-15T22:21:33+00:00June 15th, 2022|
